Interestingly, a prior study in HER2- has identified a different E2F Transcription Factor (E2F4) as having a role in treatment resistance in ER+ breast cancer [127] and also in the original analysis of our same ER+ cohort [48]. Here, E2F4 is linked to breast cancer.